Ocrevus access in Bangladesh: the DGDA named-patient pathway

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Bangladesh access Ocrevus (ocrelizumab) for relapsing and primary progressive multiple sclerosis through the DGDA named-patient pathway, a Directorate General of Drug Administration-administered mechanism that allows a Bangladeshi-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in BDT.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

Why Bangladeshi patients need Ocrevus through the named-patient pathway

The People's Republic of Bangladesh operates a structured pharmaceutical regulatory environment. Ocrevus (ocrelizumab) is regulated through DGDA (Directorate General of Drug Administration) channels, and a Bangladeshi family asking for Ocrevus is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.

Four converging patterns drive these cases. First, indication lag. Ocrevus's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Bangladesh or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.

In each pattern, the DGDA named-patient pathway is the mechanism that connects a Bangladeshi-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Ocrevus is a humanised anti-CD20 monoclonal antibody that depletes CD20-positive B lymphocytes implicated in MS pathophysiology, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.

Current regulatory status of Ocrevus in Bangladesh

Ocrevus (ocrelizumab; Genentech / Roche) is a humanised anti-CD20 monoclonal antibody for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis, administered by IV infusion as two 300 mg doses two weeks apart at induction and a single 600 mg dose every six months thereafter. As of 2026-05-31, the DGDA Registered Imported Drugs list contains no public record of a Bangladesh marketing authorisation for ocrelizumab.

Bangladeshi MS patients seeking ocrelizumab therefore route under Section 13 of the Drugs (Control) Ordinance 1982 as a case-by-case import permission, customarily through the National Institute of Neurosciences and Hospital (NINS) pharmacy or BSMMU Neurology. The file specifies the McDonald 2017 diagnostic criteria reference, the EDSS baseline score, and prior disease-modifying-therapy history including any natalizumab-related JC-virus-antibody-status considerations.

Because the every-six-months dosing cadence is unusually long, a single-cycle DGDA permission letter typically covers a single 600 mg infusion plus an immediately-pre-infusion premedication regimen (methylprednisolone, antihistamine, antipyretic). Two-cycle composite files (the 300 mg + 300 mg induction pair) are typically lodged together because the doses are 14 days apart.

Last DGDA bulletin observed touching imported biologic regulation: 2025-01-14 Guideline for Quality Assurance of Locally Sourced Medical Products. Last verified by ARCH-74: 2026-05-31.

Named tertiary centres in Bangladesh where Ocrevus is dispensed

Ocrelizumab is a neurology infusion product; the Bangladeshi referral centres with MS-clinic infrastructure and IV-biologic infusion capability:

• National Institute of Neurosciences and Hospital (NINS), Sher-e-Bangla Nagar, Dhaka - Department of Neurology; the national tertiary neurology centre and the principal MS-care destination for public-sector patients. Source: NINS official site.
• Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka - Department of Neurology with an MS sub-clinic; academic tertiary neurology centre.
• Dhaka Medical College Hospital, Dhaka - Department of Neurology; large-volume public tertiary.
• Square Hospitals Limited, Dhaka - private multi-specialty tertiary; neurology and infusion service.
• Evercare Hospital Dhaka, Dhaka - private multi-specialty tertiary; neurology MS-care service.

The MS Society of Bangladesh (a patient-organisation, not the regulator) maintains a national referral list aligned with NINS; the society is a typical starting point for newly-diagnosed patients confirming their referral chain.

Local pricing reference for Ocrevus in Bangladesh

US WAC reference for Ocrevus (ocrelizumab, 300 mg/10 mL single-dose vial) is in the order of USD 32,000 to USD 38,000 per 600 mg six-monthly maintenance dose at the FDA-labelled regimen; the two-vial induction is in the same per-vial price band administered as two doses. Source: Ocrevus FDA Prescribing Information.

No public BDT reference price for ocrelizumab has been observed on DGDA, NINS, BSMMU, or major-importer published lists as of 2026-05-31. Importers customarily quote BDT at the spot USD/BDT rate published by Bangladesh Bank on the day of the proforma invoice plus permit, cold-chain logistics, and infusion-service overhead. We issue an itemised quotation at intake with the day-of-quote conversion shown.

Price snapshot date: 2026-05-31. Pre-medication regimen (methylprednisolone 100 mg IV, antihistamine, antipyretic) and infusion-chair charges are billed by the dispensing hospital separately.

Country-specific access barriers for Ocrevus in Bangladesh

The six-month dosing cadence is materially favourable for Bangladeshi MS patients because each infusion permission is independent and patients are not locked into a chronic monthly schedule for which permit-renewal cadence would be cumbersome. The principal barrier is therefore not paperwork; it is the binding requirement for hepatitis-B surface-antigen screening at baseline (Ocrevus boxed warning addresses hepatitis-B reactivation risk) and JC-virus-antibody screening where prior natalizumab exposure is documented.

Public-sector funding for MS-DMT in Bangladesh is constrained. The Ministry of Health and Family Welfare procurement budget covers interferon-beta (a generic local-registration product) and some glatiramer-acetate biosimilar; ocrelizumab is not on the locally-procured drug list. The Honourable Prime Minister's Welfare Fund processes high-cost-medicine case applications; MS cases have been approved on individual merit historically.

Private-insurance coverage of ocrelizumab is policy-specific. Group-corporate plans (Pragati Life, Delta Life, MetLife Bangladesh, Green Delta, Pioneer) cover formal-sector employees with annual maximums that typically cover one six-monthly cycle. The dominant funding pattern for ongoing maintenance is patient self-pay supplemented by family savings and remittances; Roche's regional patient-access programme operates for ocrelizumab and accepts Bangladesh files on a case-by-case basis.

The MS-DMT class is dispensed at infusion centres; Ocrevus's 600 mg dose is administered as a 3.5-hour IV infusion (or a 2-hour shorter-infusion regimen after Cycle 1) under continuous monitoring for infusion reactions. The dispensing hospital must therefore have a neurology infusion bay with monitoring; this is not a barrier at the named Dhaka tertiary centres above but does concentrate access there.

Recent local regulatory news touching Ocrevus or its drug class in Bangladesh

No DGDA bulletin specifically naming ocrelizumab, the anti-CD20 monoclonal class for MS, or the McDonald 2024 criteria refresh has been observed in the last twelve months on the DGDA all-categories notices page as of 2026-05-31. Adjacent regulatory context relevant to the workflow:

• 2025-01-14 - DGDA Guideline for Quality Assurance of Locally Sourced Medical Products tightens lot-by-lot QA expectations for imported biologic finished products. Source: DGDA Guideline PDF.
• The Bangladesh medicine-regulation reform Bill (planned 1982 Ordinance replacement) is in active consultation and may restructure the case-by-case import-permission mechanism currently used for MS-DMT biologics. Source: Dhaka Tribune coverage.

What your physician needs to provide

For a Bangladeshi-licensed specialist prescribing Ocrevus through the DGDA pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for relapsing and primary progressive multiple sclerosis, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Ocrevus is the appropriate next step given a humanised anti-CD20 monoclonal antibody that depletes CD20-positive B lymphocytes implicated in MS pathophysiology.

The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Ocrevus (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.

The treating physician's Bangladeshi license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.

What to monitor on Ocrevus

Ocrevus sits in the anti-CD20 class with Briumvi (ublituximab) and Kesimpta (ofatumumab). Four safety signals stand out for the patient and the treating neurology team: hepatitis B reactivation, progressive multifocal leukoencephalopathy (PML) and JC virus, persistent hypogammaglobulinaemia, and infusion reactions. Each is described below with the monitoring cadence and the prescribing-information citation.

Hepatitis B reactivation. Pre-treatment screening for hepatitis B is mandatory before the first Ocrevus dose: HBsAg and anti-HBc (total) at minimum, with anti-HBs added where available (Ocrevus Prescribing Information, section 5.2). Patients with chronic hepatitis B require hepatology co-management and antiviral prophylaxis before B-cell depletion. Patients with resolved hepatitis B (HBsAg negative, anti-HBc positive) need a frank discussion of reactivation risk and a monitoring plan; many centres add periodic HBV DNA testing during therapy. Reference: Ocrevus (ocrelizumab) Prescribing Information, Genentech (Roche), section 5.2.

Progressive multifocal leukoencephalopathy (PML) and JC virus. Anti-CD20 therapies including ocrelizumab carry a class risk for PML, a rare and serious brain infection caused by reactivation of the JC virus in immunosuppressed patients. Symptoms include progressive limb weakness, behavioural and cognitive changes, and disturbance of vision or speech. PML cases on ocrelizumab have been reported in the post-marketing setting, including patients with no prior natalizumab exposure (Ocrevus Prescribing Information, section 5.4). Baseline JC virus antibody serology is not mandated by the FDA label, but most MS neurology programmes order it for risk stratification, particularly when sequencing onto Ocrevus from natalizumab (Tysabri). Any new neurological symptom during treatment, including symptoms that do not fit the patient's prior MS relapse pattern, warrants urgent neurology re-evaluation with MRI. Reference: Ocrevus Prescribing Information, section 5.4, US FDA approval March 2017.

Hypogammaglobulinaemia and immunoglobulin monitoring. Anti-CD20 monoclonal antibodies deplete B-lymphocytes and, with repeated dosing, reduce circulating immunoglobulin levels over time. The Ocrevus label requires baseline measurement of serum immunoglobulins (IgG, IgA, IgM) before treatment initiation, with monitoring during treatment and after discontinuation until B-cell repletion (Ocrevus Prescribing Information, section 5.7). MS-experienced centres typically check quantitative immunoglobulins at baseline and every six months at the maintenance-infusion visit. Persistent hypogammaglobulinaemia, in particular IgG below 4 g/L, increases the risk of serious bacterial infection; immunoglobulin replacement (IVIG) may be considered in consultation with immunology if levels remain low and infections recur. References: Ocrevus Prescribing Information, section 5.7; Hauser SL et al., Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis (OPERA I and II), N Engl J Med 2017;376(3):221-234.

Infusion reactions and premedication. Infusion reactions are among the most frequent adverse events in the OPERA I and II and ORATORIO trials, occurring in approximately 34 percent of Ocrevus-treated patients and most often with the first (Day 1, 300 mg) infusion. Premedication is mandatory before each infusion: methylprednisolone 100 mg IV (or equivalent corticosteroid) approximately 30 minutes pre-infusion, plus an oral or IV antihistamine such as diphenhydramine 25 to 50 mg, plus an antipyretic such as paracetamol 650 mg orally (Ocrevus Prescribing Information, section 2 dosing and administration, and section 5.1). The first dose is split into two 300 mg infusions two weeks apart, each delivered over approximately 2.5 hours with continuous observation; maintenance 600 mg infusions run over approximately 3.5 hours, or 2 hours with the shorter-infusion protocol in eligible patients. Reactions may present as throat tightness, flushing, headache, fever, urticaria, bronchospasm, or hypotension and are managed by slowing or temporarily stopping the infusion, optimising premedication, and observing recovery before resuming. Severe reactions, including anaphylaxis, require permanent discontinuation. References: Ocrevus Prescribing Information, section 5.1 and section 2; Montalban X et al., Ocrelizumab versus placebo in primary progressive multiple sclerosis (ORATORIO), N Engl J Med 2017;376(3):209-220.

Common questions about Ocrevus in Bangladesh

Will out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Ocrevus is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by DGDA? The DGDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; DGDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Bangladeshi-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Bangladesh Medical and Dental Council (BMDC) and the DGDA verifies the active license; the DGDA application records both the prescribing physician and the dispensing facility.

Can I receive Ocrevus at home? The dispensing facility must be Bangladeshi-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Where Reserve Meds fits in Ocrevus cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DGDA, and we do not replace your dispensing pharmacy. For Ocrevus specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Bangladesh, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Ocrevus case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DGDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Bangladeshi tertiary specialty care concentrates at Square, Apollo Imperial, United, Evercare, and Labaid in Dhaka; the DGDA named-patient import authorisation is the standard mechanism for unregistered specialty medicines and is typically filed by the treating consultant at one of these centres.

Next step

If your Bangladeshi physician has prescribed Ocrevus and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Reserved for you.

---

Related

• Ocrevus drug overview
• Bangladesh country page
• Named-patient pathway overview